Tag: chest

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

Dr. Juan Pablo Umaña Joins the Miller School and UHealth as Chief of Cardiothoracic Surgery

MIAMI, June 23, 2025 /PRNewswire/ -- The Miller School of Medicine and UHealth – University of Miami Health System welcome Juan Pablo Umaña, M.D., an...

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome...

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Haier Ranks First in Industry on the Top 50 2025 Chinese Global Brand Builders List, Maintains Top 10 Position for 9 Consecutive Years

LINGSHUI, China, June 19, 2025 /CNW/ -- Haier has once again secured the top position in the home appliance category on the prestigious Top...

Huxley Medical Shares New Data at SLEEP Demonstrating Breadth of Clinical Insights Enabled by SANSA Diagnostic Platform

SEATTLE, June 18, 2025 /PRNewswire/ -- Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced the...

The 4th Edition of AMSC Malaysia Returns in 2025: Uniting Global Leaders in Aesthetic Medicine, Dermatology, and Surgery

KUALA LUMPUR, Malaysia, June 16, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its highly anticipated fourth edition...

Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China

SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

BIG3 adds GameAbove Sports as National Jersey Partner

GameAbove Sports to Receive Jersey Patch Across Five Key BIG3 Markets LOS ANGELES, June 13, 2025 /PRNewswire/ -- Today, the BIG3 announced that GameAbove Sports—the sports...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsChest

Invitation to Vitrolife Group’s presentation of the Q2 2025 interim report

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified

RedCloud Announces Pricing of $13.5 Million Private Placement of Securities